MKMia Elena Koponen

Mia Elena Koponen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mia Elena Koponen has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Identifying predictors of neuropathic pain medication prescribing, adherence, and discontinuation: a systematic review and meta-analysis

    by Mia E. Koponen, Dhaneesha N.S. Senaratne, Harry L. Hébert, Blair H. Smith, Lesley A. Colvin


  • Open Access

    Identifying predictors of neuropathic pain medication prescribing, adherence, and discontinuation: a systematic review and meta-analysis

    by Mia Elena Koponen, Dhaneesha N. S. Senaratne, Harry Lidstone Hebert, Blair Hamilton Smith, Lesley A. Colvin

    Background Pharmacoepidemiological studies show that large proportions of people with neuropathic pain (NP) are not prescribed the medications recommended for NP, do not adhere well to these medications, and/or often discontinue the treatment within half a year. Identifying what predicts these outcomes can inform a strategy to ensure that people with NP are prescribed recommended medication and continue their treatment when appropriate. Methods We carried out a systematic review and meta-analysis to identify predictors of pain medication prescribing, adherence, and discontinuation in adults with NP (PROSPERO ID: CRD42023464307). Electronic searches were conducted in Embase, PubMed, Web of Science, and CINAHL Plus. Results We identified 60 relevant studies and divided them into non-mutually exclusive categories based on the outcomes they had investigated. There were 45 studies on prescribing, 14 on adherence, and 25 on discontinuation. Predictors associated with being prescribed recommended NP medications as the first choice included white ethnicity, having diabetes, and/or having a mental health disorder. Predictors associated with better adherence included being prescribed serotonin-norepinephrine reuptake inhibitors compared to gabapentinoids or tricyclic antidepressants; dose titration, and/or implementing a medicine reminder. Predictors associated with a higher likelihood of discontinuation included being prescribed medications other than second-generation antidepressants and/or having a combination of NP medications rather than a single medication. Conclusions Thus, there is a need to focus on improving NP medication prescribing for ethnic minorities and people with non-diabetic NP. Adherence and persistence with NP medications could be improved by prioritising the prescribing of serotonin-norepinephrine reuptake inhibitors if indicated.

  • Open Access

    Pharmacological interventions for remifentanil-induced hyperalgesia: A systematic review and network meta-analysis of preclinical trials

    by Mia E Koponen, Emily Naray, Tim G Hales, Patrice Forget

    Background: To improve perioperative pain management, several interventions have been suggested for the prevention of increased pain sensitivity caused by opioids (called opioid-induced hyperalgesia). It is currently unclear which intervention is the most effective or appropriate in preventing opioid-induced hyperalgesia. Remifentanil is the most investigated opioid causing opioid-induced hyperalgesia. Thus, to guide future research, we conducted a systematic review and a network meta-analysis of preclinical trials investigating pharmacological interventions for remifentanil-induced hyperalgesia. Methods: To identify relevant articles, electronic database searches were conducted in Embase, PubMed, Web of Science, and Google Scholar. Study characteristics were extracted, and the risk of bias was evaluated. Studies were included in the network meta-analysis if they shared similar characteristics with at least one other study. The interventions were ranked based on P-scores. Results: Overall, the 62 eligible trials tested 86 individual interventions and 6 combination interventions. Thirty-five studies eligible in the network meta-analysis formed five groups which were further divided into subgroups based on the quantitative sensory tests used. The best-ranked interventions within the subgroups were Anxa12-26, MRS2179, salicylaldehyde isonicotinoyl hydrazone (SIH), ANA-12, TDZD-8, ketamine, dexmedetomidine, JWH015, and the combination of KN93 and ketamine. Discussion: The current literature is too heterogeneous to produce a clear answer on which intervention is the most effective in preventing remifentanil-induced hyperalgesia. Future research in this field should prioritise finding the most effective intervention over testing the efficacy of new options. The results of our work can be used in planning which comparisons should be included in new trials.


  • Open Access

    Impact of adverse childhood experiences on analgesia-related outcomes: a systematic review

    by Dhaneesha N.S. Senaratne, Mia Koponen, Karen N. Barnett, Blair H. Smith, Tim G. Hales, Louise Marryat, Lesley A. Colvin


  • Open Access

    Pharmacological Interventions for Opioid-Induced Hyperalgesia: A Scoping Review of Preclinical Trials

    by Mia Elena Koponen, Patrice Forget

    Background: Opioid analgesics are the most effective pharmacological agents for moderate and severe pain. However, opioid use has several limitations such as opioid-induced hyperalgesia (OIH), which refers to the increased pain sensitivity that occurs once analgesia wears off after opioid administration. Several pharmacological interventions have been suggested for OIH, but the current literature does not provide guidelines on which interventions are the most effective and whether they differ depending on the opioid that induces hyperalgesia. This scoping review aimed to identify and describe all the preclinical trials investigating pharmacological interventions for OIH caused by remifentanil, fentanyl, or morphine as the first step towards evaluating whether the most effective OIH interventions are different for different opioids. Methods: Electronic database searches were carried out in Embase, PubMed, and Web of Science. Detailed data extraction was conducted on the eligible trials. Results: 72 trials were eligible for the review. Of these, 27 trials investigated remifentanil, 14 trials investigated fentanyl, and 31 trials investigated morphine. A total of 82 interventions were identified. The most studied interventions were ketamine (eight trials) and gabapentin (four trials). The majority of the interventions were studied in only one trial. The most common mechanism suggested for the interventions was inhibition of N-methyl-D-aspartate (NMDA) receptors. Conclusion: This scoping review identified plenty of preclinical trials investigating pharmacological interventions for OIH. Using the current literature, it is not possible to directly compare the effectiveness of the interventions. Hence, to identify the most effective interventions for each opioid, the interventions must be indirectly compared in a meta-analysis.